- Algernon Pharmaceuticals (AGN) has completed enrollment in its Phase 2 NP-120 IPF and chronic cough study
- This 20 patient Phase 2 human trial will study the efficacy of Ifenprodil in the preservation of lung function in IPF patients
- Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a mouse model of IPF
- Algernon is a drug re-purposing company that investigates already approved drugs for new disease applications
- Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$7.31
Algernon Pharmaceuticals (AGN) has completed enrollment in its Phase 2 NP-120 (Ifenprodil) idiopathic pulmonary fibrosis (IPF) and chronic cough study.
The company is projecting a data readout in calendar Q2, 2022.
“We are very pleased to announce this update to the market on our IPF and chronic cough study and we look forward to having it completed and presenting the data,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
The purpose of this 20 patient Phase 2 human trial is to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients and its associated cough. Seven sites are participating in the study: 5 in Australia and 2 in New Zealand.
Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a mouse model of IPF. In addition, Ifenprodil significantly both reduced cough frequency and delayed onset in a guinea pig acute cough model.
Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, neutrophils and certain types of cancer cells.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.
Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$7.31.